Skip to main content

Table 9 Characteristics of studies included based on treatment regiments: carboplatin + eribulin

From: Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis

 

Affiliation

Type of study

Stage of disease

Median age

Nº of BRCA1/2 mutated TNBC patients

pCR

Neoadjuvant treatment

Kaklamani 2015 [50]

USA

Phase II Clinical Trial

II-III

52,5

3

2

Cb-Er

  1. pCR Pathological complete response, Cb Carboplatin, Er Eribulin
Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287